Outcomes in systemic sclerosis-related lung disease after lung transplantation

Transplantation

Volumn 95, Issue 7, 2013, Pages 975-980

  Sottile, Peter D ^a   Iturbe, David ^b   Katsumoto, Tamiko R ^a   Connolly, M Kari ^a   Collard, Harold R ^a   Leard, Lorriana A ^a   Hays, Steven ^a   Golden, Jeffrey A ^a   Hoopes, Charles ^c   Kukreja, Jasleen ^a   Singer, Jonathan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Bronchiolitis obliterans syndrome; Esophageal dysmotility; Interstitial lung disease; Lung transplantation; Survival; Systemic sclerosis

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; BRONCHIOLITIS OBLITERANS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL PH MONITORING; ESOPHAGUS DISEASE; ESOPHAGUS MANOMETRY; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL MOTILITY DISORDER; GRAFT SURVIVAL; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCORING SYSTEM; SURVIVAL TIME; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 84876206228     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182845f23     Document Type: Review

References (25)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940.
2. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151.
3. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026.
4. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962.
5. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxf ) 2006; 45: 1005.
6. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 updateVa consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745.
7. Gasper WJ, Sweet MP, Golden JA, et al. Lung transplantation in patients with connective tissue disorders and esophageal dysmotility. Dis Esophagus 2008; 21: 650.
8. D'Ovidio F, Singer LG, Hadjiliadis D, et al. Prevalence of gastro-esophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005; 80: 1254.
9. Denton CP, Lapadula G, Mouthon L, et al. Renal complications and scleroderma renal crisis. Rheumatology (Oxf ) 2009; 48: iii32.
10. Saggar R, Khanna D, Furst DE, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010; 36: 893.
11. Shitrit D, Amital A, Peled N, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009; 23: 178.
12. Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idio-pathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54: 3954.
13. Massad MG, Powell CR, Kpodonu J, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005; 29: 1510.
14. Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000; 5: 38.
15. Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med 2011; 184: 159.
16. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010; 37: 42.
17. Pakozdi A, Nihtyanova S, Moinzadeh P, et al. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 2011; 38: 2406.
18. Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581.
19. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202.
20. Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
22. Laszlo G. Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax 2006; 61: 744.
23. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.
24. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
25. Sottile PD, Iturbe D, Golden JA. Outcomes in scleroderma-related interstitial lung disease following lung transplant [abstract]. J Heart Lung Transplant 2011: 30: S204.